| Literature DB >> 21513568 |
Yoon Jee Lee1, Jaehee Lee, Yi Young Kim, Dong Il Won, Seung Ick Cha, Jae Yong Park, Tae Hoon Jung, Chang Ho Kim.
Abstract
BACKGROUND: This study was conducted to evaluate the performance of a whole-blood interferon-gamma release assay in inpatients who were admitted to the emergency department (ED) with pulmonary infiltrates who required a differential diagnosis with pulmonary tuberculosis (TB).Entities:
Mesh:
Substances:
Year: 2011 PMID: 21513568 PMCID: PMC3107174 DOI: 10.1186/1471-2334-11-107
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Baseline characteristics of the study population
| Characteristics | Inpatients | Outpatients | ||
|---|---|---|---|---|
| Total (n = 284 ) | * Non- TB (n = 196) | TB (n = 88) | TB (n = 93) | |
| Age, yr | 63 ± 16.5 | 65 ± 14.5 | 59 ± 19.8 | 52 ± 19.5 |
| Male | 206 (72.5) | 150 (76.5) | 56 (63.6) | 50 (53.8) |
| Body mass index | 21.4 ± 3.50 | 21.7 ± 3.42 | 20.8 ± 3.61 | 21.7 ± 3.08 |
| Prior TB history | 57 (20.1) | 39 (19.9) | 18 (20.5) | 16 (17.2) |
| Underlying conditions | ||||
| Renal failure | 11 (3.9) | 9 (4.6) | 2 (2.3) | 0 (0) |
| Malignancy† | 4 (1.4) | 2 (1.0) | 2 (2.3) | 3 (3.2) |
| Immunosuppressive therapy‡ | 11 (3.9) | 7 (3.6) | 4 (4.5) | 0 (0) |
Data are shown as mean ± SD or No. (%). TB, tuberculosis.
* Patients with pneumonia (n = 178), organizing pneumonia (n = 7), nontuberculous mycobacterial lung disease (n = 5), aspergillosis (n = 4), and lung cancer (n = 2).
† Patients with a diagnosis of cancer who were not receiving anti-cancer treatment, including lung cancer (n = 2), hypopharyngeal cancer (n = 1), and gastric cancer (n = 1) for inpatients; hepatocellular carcinoma (n = 1), glottic cancer (n = 1), and gastric cancer (n = 1) for outpatients.
‡ Patients receiving cancer chemotherapy (n = 9 ) or systemic steroids (>10 mg/day of prednisone for ≥ 1 month) (n = 2).
Performance of QuantiFERON test in inpatients with pulmonary infiltrates and outpatients with pulmonary tuberculosis
| QuantiFERON† | Inpatients | Outpatients | ||||
|---|---|---|---|---|---|---|
| Total | * Non-TB | TB | TB | |||
| Indeterminate | 84 (29.6) | 69 (35.2) | 15 (17.0) | 0.002 | 1 (1.1) | <0.001 |
| Determinate | 200 (70.4) | 127 (64.8) | 73 (83.0) | 92 (98.9) | <0.001 | |
| Positive | 77 (27.1) | 26 (13.3) | 51 (58.0) | 77 (82.8) | ||
| Negative | 123 (43.3) | 101 (51.5) | 22 (25.0) | 15 (16.1) | ||
Data are shown as mean ± SD or No. (%). TB, tuberculosis.
† QuantiFERON test was performed by using QuantiFERON®- TB Gold or QuantiFERON ®-TB Gold In-Tube.
* Patients with pneumonia (n = 178), organizing pneumonia (n = 7), nontuberculous mycobacterial lung disease (n = 5), aspergillosis (n = 4), and lung cancer (n = 2).
Comparison of proportion of indeterminate vs. determinate results between in patients with non-TB and TB.
Comparison of proportion of indeterminate vs. determinate results between inpatients and out patients with TB.
Comparison of positive QuantiFERON test results between inpatients and outpatients with TB.
Univariate and multivariate analysis of factors associated with indeterminate QuantiFERON results in inpatients with pulmonary infiltrates
| Covariate | Determinate | indeterminate | Univariate | Multivariate | ||
|---|---|---|---|---|---|---|
| Odds ratio | 95% confidence interval | Odds ratio | 95% confidence interval | |||
| Age, yr | 62 ± 17.1 | 67 ± 14.5 | 1.018 | 1.001-1.035 | ||
| Lymphocytes cells/μL | 1170 ± 935 | 764 ± 451 | 0.999 | 0.998-0.999 | ||
| Lymphocytopenia* | ||||||
| Absence | 99 (49.5) | 19 (22.6) | 1.0 | 1.0 | ||
| Presence | 101 (50.5) | 65 (77.4) | 3.353 | 1.875-5.998 | 2.688 | 1.424-5.075 |
| Albumin, g/dL | 3.4 ± 0.60 | 3.0 ± 0.54 | 0.307 | 0.190-0.495 | 0.412 | 0.245-0.694 |
| ESR, mm/hr | 58.3 ± 35.88 | 67.2 ± 32.52 | 1.007 | 1.000-1.015 | ||
| CRP, mg/dL | 9.2 ± 8.43 | 15.7 ± 9.65 | 1.078 | 1.046-1.110 | 1.060 | 1.027-1.094 |
Data are shown as mean ± SD or No. (%).
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
QuantiFERON test was performed by using QuantiFERON®- TB Gold or QuantiFERON ®- TB Gold In-Tube.
* Lymphocytopenia; < 1,000 cells/μL.
Comparison of inpatients and outpatients with pulmonary tuberculosis with regard to the factors associated with non-positive QuantiFERON results
| Covariates | Inpatients | Outpatients | ||||
|---|---|---|---|---|---|---|
| Positive QFT | Non-positive QFT | Positive QFT | Non-positive QFT | |||
| Laboratory findings | ||||||
| WBC, cells/μL | 8566 ± 3438 | 10604 ± 5464 | 0.050 | 7723 ± 2372 | 7526 ± 2212 | 0.761 |
| Lymphocytes, cells/μL | 1203 ± 509 | 885 ± 440 | 0.003 | 1 787 ± 642 | 1508 ± 504 | 0.105 |
| Lymphocytopenia* | 20 (39.2) | 24 (64.9) | 0.018 | 7 (9.3) | 1 (7.7) | 1.0 |
| Albumin, g/dL | 3.6 ±0.64 | 3.1 ± 0.59 | 0.003 | 4.4 ± 0.40 | 4.1 ± 0.56 | 0.051 |
| ESR, mm/hr | 60.5 ± 35.15 | 62. 5 ± 35.97 | 0.806 | 33.9 ± 27.1 | 58.1 ± 33.4 | 0.004 |
| CRP, mg/dL | 6.5 ± 6.21 | 8.3 ± 6.83 | 0.230 | 2.1 ± 2.92 | 0.44 ± 0.30 | 0.452 |
| Radiographic extent of disease | ||||||
| Mild | 19 (37.3 ) | 13 (35.1 ) | 0.589 | 55 (71.4 ) | 6 (37.5) | 0.020 |
| Moderate | 19 (37.3) | 11 (29.7 ) | 21 (27.3) | 10 (62.5) | ||
| Advanced | 13 (25.5) | 13 (35.1) | 1 (1.3) | 0 | ||
Data are shown as mean ± SD or No. (%).
WBC, white blood cells; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; QFT = QuantiFERON (performed by QuantiFERON®-TB Gold or QuantiFERON®-TB Gold In-Tube).
* Lymphocytopenia; < 1,000 cells/μL.